George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have considered the lag time from offering the test to the market to initial supply. Necessarily, the test had to complete CV for CE marking / MHRA approval. That was only a handful of trading sessions ago.
The fact that the test was thereafter immediately for sale does not and can not mean boxes of AffiDx would fly off the shelves the next day. Any contract would require forward projection of orders and the assurance to supply them. As the nascent U.K. LFT industry is still spinning up, that’s a question that will take a bit of time to answer.
Notwithstanding all the nonsense going on at PD and the possible U.K. Govt involvement, the test is on the market and now it’s a question of supply before final contracts can be inked.
Imagine say, Aston Martin developed an affordable car that was in great demand, worldwide. It was widely regarded as the Best Car In The World and everyone wanted one - and it could be produced in the millions. Firstly, nobody would put an order in until it had been *proven* to be the best. Because there were many similar cars out there that claimed to be The Best. Furthermore, until they could *guarantee* how many they could roll off the conveyor belt every month, contracts would be impossible to draw up for dealerships. Especially difficult as the global dealership networks were all showing interest.
The CV data demonstrates we have The Best Test. The global demand is there. The competition has been thrown in the trash. What we must be dealing with here is how big is the queue to get our test and when can we start rolling them off the production lines in the quantities desired. Fascinating stuff.
It's Avacta all the way from here.
That's the point. They won't be given green light status *ever* with their current test.
Innova is explicitly used as a red light test.
Ndn has chosen this as the latest way to troll Avacta on Twitter.
They won’t be extended. They will be exempt from the new legislation, although I’d personally argue that the use of their test has never been properly evaluated as the instructions for use don’t match the original manufacturer IFU.
Innova won't be exempted or extended beyond the two months. As I've said before, MHRA Buying Time to Investigate Innova:
https://www.lse.co.uk/ShareChat.asp?ShareTicker=AVCT&share=Avacta&thread=5D495A04-3897-44AA-BC4E-5DB89C963E8F
I wouldn’t put anything past the government. They’ll likely use the Innova tests for as long as they can. In whatever capacity they can.
Plus the Innova test is not particularly pleasant to self administer as per the instructions and therefore unlikely to get used properly.
Maybe, the MHRA weren’t happy for it being used in this way, but then they also just gave them an extension until the new legislation kicks in that gives them a free pass. That’s even though it’s not suitable and doesn’t perform well enough for this purpose. Who knows, perhaps they’ll show a bit of interest in an easy to use British test that’s perfectly suited and performs exceptionally well. Time will tell.. meanwhile europe and the rest of the planet awaits.
Innova is test to isolate.
Won't they just use innova for the test to release scheme?
Someone receiving Innova tests from the NHS isn’t a shocker, we need to find someone who is part of the test to release LFD trial….
John Xiamen biotime is Innova
For a test to release trial?
I have ordered the test through NHS Scotland..arrived today ..I have posted pictures of the test on twitter with the Avct # ..its Chinese made and I have asked for information on the maker.
They’ve said it’s a trial. There’s no reason to believe it won’t be a success if they’re using AffiDx. There’s little urgency though, they could have cracked on a while ago - unless they’ve been awaiting MHRA registration of a suitable test before inking a deal. I suspect that the dither has also been related to pushing vaccines. This is a good combo of carrot and stick. Get your vaccines and then if you’re traced you don’t need to isolate via testing. Works for everyone.
Avacta?
Just heard this on Radio 2 news. Rather than having to self isolate for 10 days people are expected to self test daily using LFT’s (which you assume would have to be easy to use and highly accurate - I wonder who’s test that might be?)
I'm glad the penny is starting to drop.
Big announcement next week regarding test and release.
With mologic taking UK Gov to court and Innova clearly not good enough to be used as a test and release LFT I'd say this is looking very positive for Avacta.